Health TrialsbyHealthPanel

Giessen Pulmonary Hypertension in Lung Cancer Registry

ConditionPulmonary Hypertension Due to Lung Diseases and Hypoxia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Giessen

About this trial

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient with lung cancer at the University of Giessen lung Cancer Center.

Disqualifiers

None

Trial population

Equivalent to the average of patients with lung cancer in Germany.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • All lung cancer patients.

    Other intervention

    There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.

Treatment groups

500 Participants
are divided into 1 treatment group
Group A: All lung cancer patients1 intervention

Trial outcomes

Primary outcomes

1

Pulmonary function test measured via Spirometry.

vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.

Time frame
2 years
2

sPAP values measured via Echocardiography.

systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).

Time frame
2 years
3

Body mass index.

weight and height will be combined to report BMI in kg/m\^2.

Time frame
2 years
4

Overall Survival and Progression Free Survival measured in days.

Overall Survival and Progression free survival in days will be determined by Kaplan-Meier Analysis .Measuared in (st) (time from diagnosis to death)

Time frame
2 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Giessen

Lead sponsor

Source ClinicalTrials.gov
Apply now